NCT02844309 2026-02-11
BDH-WM02
Institute of Hematology & Blood Diseases Hospital, China
Phase 4 Completed
Clinical Trials
141 trialsNCT00769587 2025-09-22
Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis
Centre Hospitalier Universitaire, Amiens
Completed
NCT01998971 2025-04-25
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Phase 1 Completed
NCT02541383 2025-04-13
Cassiopeia
Intergroupe Francophone du Myelome
Phase 3 Completed
NCT01539083 2025-02-04
VCAT
Janssen Scientific Affairs, LLC
Phase 3 Completed
NCT02507336 2024-08-01
Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165
University of Miami
Phase 2 Completed
NCT02586038 2024-05-08
STUDY THAT COMPARE 3 ARM: MLN9708 DEXAMETHASONE, MLN9708 CYCLOPHOSPHAMIDE AND DEXAMETHASONE, MLN9708 THALIDOMIDE AND DEXAMETHASONE FOLLOWED BY MAINTENANCE WITH MLN9708 IN NEWLY DIAGNOSED ELDERLY MULTIPLE MYELOMA PATIENTS
University of Turin, Italy
Phase 2 Completed
NCT02891811 2024-03-29
Patients With Newly Diagnosed Multiple Myeloma Comparing KTd vs. KRd Induction Therapy and Investigating a K-mono Maintenance Strategy
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT00019539 2024-03-04
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00020046 2023-10-31
Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00049673 2023-09-13
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
Canadian Cancer Trials Group
Phase 3 Completed
NCT00054158 2022-10-03
Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma
Roswell Park Cancer Institute
Phase 2 Completed
NCT01849783 2022-05-11
Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma
University of Iowa
Phase 2 Completed
NCT02424851 2022-01-27
OPTIMAL
Oxford University Hospitals NHS Trust
Phase 2 Completed
NCT01125176 2022-01-21
ThRiL
Weill Medical College of Cornell University
Phase 2 Completed
NCT00075829 2021-11-01
BMT CTN 0102
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00112502 2021-10-18
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00049361 2021-09-09
Radiation Therapy Plus Thalidomide and Temozolomide in Treating Patients With Newly Diagnosed Brain Metastases
Wake Forest University Health Sciences
Phase 2 Completed
NCT00079092 2021-09-09
Thalidomide and Procarbazine in Treating Patients With Recurrent or Progressive Malignant Glioma
Wake Forest University Health Sciences
Phase 2 Completed
NCT00792142 2021-08-19
Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT00538733 2021-05-24
T-BiRD
Weill Medical College of Cornell University
Phase 2 Completed
NCT02545907 2021-04-15
CATALYST
University College, London
Phase 1/2 Completed
NCT00966693 2020-11-04
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00033254 2020-10-30
Radiation Therapy With or Without Thalidomide in Treating Patients With Brain Metastases
National Cancer Institute (NCI)
Phase 3 Completed
NCT00006890 2020-04-02
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Canadian Cancer Trials Group
Phase 2 Completed
NCT02410694 2019-12-13
Ixazomib in Combination With Thalidomide - Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
Arbeitsgemeinschaft medikamentoese Tumortherapie
Phase 2 Completed
NCT00689936 2019-11-20
FIRST
Celgene
Phase 3 Completed
NCT00452569 2019-11-18
OPTIMUM
Celgene
Phase 3 Completed
NCT00657488 2019-10-18
Thalidomide 100 mg/Day Versus Thalidomide 400 mg/Day in Relapse Refractory Multiple Myeloma
Celgene
Phase 2/3 Completed
NCT00049374 2019-10-17
Oblimersen, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma
University of Maryland, Baltimore
Phase 2 Completed
NCT00041080 2019-07-30
Tamoxifen Compared With Thalidomide in Treating Women With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT00025220 2019-07-23
Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus
National Cancer Institute (NCI)
Phase 2 Completed
NCT00004088 2019-07-02
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
City of Hope Medical Center
Phase 2 Completed
NCT00179881 2019-02-05
Thalomid and Carboplatin for the Treatment of Pediatric Brain Stem Glioma
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 2 Completed
NCT00038181 2018-11-15
Preoperative Thalidomide Followed By Radical Retropubic Prostatectomy In Select Patients With Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00527657 2018-11-14
Temozolomide, Thalidomide, and Lomustine (TTL) in Melanoma Patients
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00038090 2018-10-31
Thalidomide-Dexamethasone for Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2/3 Completed
NCT00038233 2018-10-31
Thalidomide for Multiple Myeloma
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00038246 2018-10-31
Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00310076 2018-08-23
Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer
Wake Forest University Health Sciences
Phase 2 Completed
NCT00064337 2018-08-09
S0115, High-Dose Melphalan and Autologous Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Primary Systemic Amyloidosis
SWOG Cancer Research Network
Phase 2 Completed
NCT00232934 2018-08-02
Melphalan, Prednisone and Thalidomide Versus Melphalan and Prednisone in Elderly Myeloma Patients
Gruppo Italiano per lo Studio del Mieloma Multiplo
Phase 3 Completed
NCT01526694 2018-07-03
Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM
Azienda Ospedaliera di Bolzano
Phase 2 Completed
NCT00006358 2018-06-26
Temozolomide Plus Thalidomide in Treating Patients With Recurrent or Progressive Brain Tumor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT00089609 2018-04-20
Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00287872 2018-03-01
Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT03402295 2018-01-18
GBRAM003r
Grupo de Estudos Multicentricos em Onco-Hematologia
Phase 3 Completed
NCT00081939 2017-10-17
UARK 2003-33, Total Therapy III
University of Arkansas
Phase 2 Completed
NCT00047281 2017-07-11
Thalidomide, Celecoxib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Malignant Glioma
Dana-Farber Cancer Institute
Phase 2 Completed
NCT00047294 2017-07-11
Temozolomide, Thalidomide, and Celecoxib Following Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Dana-Farber Cancer Institute
Phase 2 Completed